Exosomes as Biomarkers for Identification Quantitation and Stratification of Chronic Lymphocytic Leukemia

Sapir Cohen, Chemical Engineering, Ariel University, Ariel, Israel
Galia Luboshits , Chemical Engineering, Ariel University, Ariel, Israel
Michael A. Firer, Chemical Engineering, Ariel University, Ariel, Israel

Chronic Lymphocytic Leukemia (CLL) is the most common type of adult leukemia in western countries. CLL is a molecular and clinically heterogeneous disease and clinical staging is commonly made according to the Rai or Binet classifications. New molecular therapies for CLL have recently entered the clinic, but their long-term efficacy ultimately relies of correct and efficient stratification of patients. Additional biomarkers have also been tested but they are currently limited in their reliability and reproducibility. Research indicates that exosomes may play an important role in the development and progression of CLL, raising the prospect that easy detection of CLL-derived exosomes may lead to improved patient stratification and treatment. Exosomes are small microvesicles of 50-100nm diameter secreted by cells into the extracellular environment. They interact with other cells and influence intercellular communication in both homeostasis and disease states. They are recognized as important components of the tumor microenvironment, are involved in cancer metastasis and may play an important role in the progression and survival of CLL cells.

We developed a new method of identification of the CLL stage based on exosome markers. Using the phage display technology, we discovered 4 peptides, which specifically interact with CLL exosomes. We validated high specificity of these peptides to CLL exosomes by flow cytometry. We plan to further develop peptides that can be used for identification of CLL stages. This technology will simplify diagnostics and improve therapy outcomes.dy of your abstract here